Ilaria Marrocco
Rehovot, M 76100, Israel
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 23 publications
Strategies to Overcome Resistance to Osimertinib in EGFR-Mutated Lung Cancer.
Journal: International journal of molecular sciences
Published: February 24, 2025
A bispecific antibody targeting EGFR and AXL delays resistance to osimertinib.
Journal: Cell reports. Medicine
Published: December 18, 2023
L858R emerges as a potential biomarker predicting response of lung cancer models to anti-EGFR antibodies: Comparison of osimertinib vs. cetuximab.
Journal: Cell reports. Medicine
Published: September 07, 2022
ERp57 chaperon protein protects neuronal cells from Aβ-induced toxicity.
Journal: Journal of neurochemistry
Published: February 16, 2022
EGFR in Cancer: Signaling Mechanisms, Drugs, and Acquired Resistance.
Journal: Cancers
Published: May 05, 2021
Roles for growth factors and mutations in metastatic dissemination.
Journal: Biochemical Society transactions
Published: March 26, 2021
Host-Dependent Phenotypic Resistance to EGFR Tyrosine Kinase Inhibitors.
Journal: Cancer research
Published: October 22, 2020
Targeting HER3, a Catalytically Defective Receptor Tyrosine Kinase, Prevents Resistance of Lung Cancer to a Third-Generation EGFR Kinase Inhibitor.
Journal: Cancers
Published: July 23, 2020
Upfront admixing antibodies and EGFR inhibitors preempts sequential treatments in lung cancer models.
Journal: EMBO molecular medicine
Published: July 20, 2020
Roles for receptor tyrosine kinases in tumor progression and implications for cancer treatment.
Journal: Advances in cancer research
Published: June 29, 2020
Last Updated: 09/26/2026